Last month, the Dutch Ministry of Health, Welfare and Sport (VWS) announced that it will not include the breast cancer drug Trodelvy (sacituzumab govitecan-hziy) in the country’s standard package of pharmacy and medical benefits.
Dutch Ministry Of Health Will Not Reimburse Gilead’s Breast Cancer Drug, Trodelvy
